Mentari Therapeutics presents migraine drug pipeline, targets first clinical data in 2027
MTRI•Mentari Therapeutics expects Phase 1 data for migraine candidate MT-002 by year-end and is targeting a first-quarter 2027 regulatory filing. The company expects MT-001 Phase 1 data in mid-2027 and initial Phase 2 migraine data in 2028; it says it has raised about $490 million to date.
1. Pipeline timeline
Mentari Therapeutics outlined a five-program antibody pipeline. Its MT-002 candidate targets both PACAP and CGRP and is being developed for migraine prevention. The company expects Phase 1 data by year-end and is targeting a first-quarter 2027 regulatory filing. MT-001 Phase 1 data are expected in mid-2027, followed by initial Phase 2 proof-of-concept data in migraine patients in 2028. Mentari said it has raised about $490 million to support development beyond key anticipated milestones.
